2025 has been one of the most impactful years to date for GFCT. Our aim has always been to make early detection accessible and support better diagnosis and treatment pathways for prostate cancer and beyond.
PSA & Health Testing
Throughout the year, GFCT continued to deliver PSA testing through community events, workplace programmes and home testing kits. Over 240,000 men have now been tested since the charity began, with 2025 contributing significantly to that total. These tests continue to lead to early detection of prostate cancer for men who had no symptoms and would otherwise not have been tested.
Alongside PSA testing, our health testing programme has grown in popularity this year. Thousands of people accessed blood tests for cholesterol, diabetes, thyroid function, vitamin D and B12, liver and kidney function, iron levels and female hormones. Our data shows that around 39% of people tested fall outside normal ranges, showing the importance of routine health checks.
National Recognition and Awareness
One of GFCT’s managed PSA screening events in Torquay received national BBC coverage, including BBC News and BBC Spotlight. This helped highlight community-based testing for men who may not engage with healthcare services otherwise.
We have received many powerful testimonials of patient journeys that can be read here.
Supporting Diagnosis and Treatment
In 2025, GFCT continued to invest in its Treatment Support division, helping NHS hospitals access better diagnostic and treatment equipment. This included funding and facilitating access to HIFU and biopsy systems, with new installations and rentals confirmed for multiple NHS sites.
By supporting hospitals directly, the charity helped speed up diagnosis and reduce delays for men already in the system, ensuring testing leads to a supported diagnosis and treatment pathway. Read more about GFCT Treatment Support here.
Clinical Engagement and Partnerships
GFCT strengthened relationships with clinicians, nurses and healthcare organisations across the UK. Attendance at BAUN 2025 in Edinburgh allowed the charity to engage directly with urology nurses, showcase equipment it has funded, and recruit clinical support for future testing events.
The charity also continued collaborations with University of Manchester and medical partners, contributing data and insight to research projects aimed at improving prostate cancer screening pathways. Read about our Knowledge Empowers Conference here.
Campaigning and Policy Input
Throughout the year, we remained active in national discussions around prostate cancer screening. Our founder, Graham Fulford MBE, attended the All Party Parliamentary Group at the House of Commons in October, hosted by PCR, for the launch of their landmark report, “Prostate Cancer Screening: The Impact on the NHS.”
Graham’s Journey
This year also became deeply personal for GFCT. Our founder, Graham, has been on his own journey with prostate cancer. Thankfully, his condition is currently stable and under control. Throughout this period, Graham has continued to lead the charity with the same energy and commitment, driving forward testing, awareness and treatment support while experiencing first-hand the importance of early detection and ongoing monitoring. His experience has only strengthened the mission at the heart of GFCT.
Thank You
Thank you to everyone who supported, volunteered, partnered with or took part in GFCT’s work this year. Every test taken helps move the needle on early detection. Happy New Year!